T. Rowe Price Associates’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $10.2M | Sell |
|
|||||
|
2025
Q2 | $34.6M | Buy |
|
|||||
|
2025
Q1 | $34.6M | Sell |
|
|||||
|
2024
Q4 | $56.7M | Sell |
|
|||||
|
2024
Q3 | $69M | Buy |
|
|||||
|
2024
Q2 | $59.2M | Buy |
|
|||||
|
2024
Q1 | $32.3M | Sell |
|
|||||
|
2023
Q4 | $24.7M | Buy |
|
|||||
|
2023
Q3 | $18.7M | Sell |
|
|||||
|
2023
Q2 | $23.8M | Sell |
|
|||||
|
2023
Q1 | $23M | Sell |
|
|||||
|
2022
Q4 | $35.7M | Sell |
|
|||||
|
2022
Q3 | $47M | Sell |
|
|||||
|
2022
Q2 | $58.5M | Sell |
|
|||||
|
2022
Q1 | $67.3M | Sell |
|
|||||
|
2021
Q4 | $141M | Buy |
|
|||||
|
2021
Q3 | $141M | Buy |
|
|||||
|
2021
Q2 | $107M | Buy |
|
|||||
|
2021
Q1 | $96.2M | Buy |
|
|||||
|
2020
Q4 | $19.5M | Buy |
|
|||||
|
2020
Q3 | $19.6M | Buy |
|